| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1803 | 2016 |
| MONARCH 3: abemaciclib as initial therapy for advanced breast cancer MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ... Journal of Clinical Oncology 35 (32), 3638-3646, 2017 | 1461 | 2017 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1225 | 2018 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1025 | 2020 |
| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 746 | 2018 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Annals of Oncology 30 (3), 397-404, 2019 | 700 | 2019 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 645 | 2013 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of Oncology 32 (12), 1475-1495, 2021 | 607 | 2021 |
| Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ... Jama 313 (13), 1347-1361, 2015 | 547 | 2015 |
| Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening S Paluch-Shimon, F Cardoso, C Sessa, J Balmaña, MJ Cardoso, F Gilbert, ... Annals of Oncology 27, v103-v110, 2016 | 447 | 2016 |
| Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers T Golan, ZS Kanji, R Epelbaum, N Devaud, E Dagan, S Holter, D Aderka, ... British journal of cancer 111 (6), 1132-1138, 2014 | 427 | 2014 |
| Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS genetics 9 (3), e1003212, 2013 | 328 | 2013 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 296 | 2021 |
| Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines M Lambertini, FA Peccatori, I Demeestere, F Amant, C Wyns, ... Annals of oncology 31 (12), 1664-1678, 2020 | 288 | 2020 |
| ESO–ESMO 4th international consensus guidelines for breast cancer in young women (BCY4) S Paluch-Shimon, F Cardoso, AH Partridge, O Abulkhair, HA Azim Jr, ... Annals of Oncology 31 (6), 674-696, 2020 | 243 | 2020 |
| ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) S Paluch-Shimon, O Pagani, AH Partridge, O Abulkhair, MJ Cardoso, ... The Breast 35, 203-217, 2017 | 241 | 2017 |
| Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ... Journal of Clinical Oncology 35 (15_suppl), 1008-1008, 2017 | 169 | 2017 |
| Second international consensus guidelines for breast cancer in young women (BCY2) S Paluch-Shimon, O Pagani, AH Partridge, E Bar-Meir, L Fallowfield, ... The Breast 26, 87-99, 2016 | 142 | 2016 |
| ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer E de Azambuja, D Trapani, S Loibl, S Delaloge, E Senkus, C Criscitiello, ... ESMO open 5, e000793, 2020 | 137 | 2020 |
| Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation … D Meirow, H Raanani, E Maman, S Paluch-Shimon, M Shapira, Y Cohen, ... Fertility and sterility 102 (2), 488-495. e3, 2014 | 131 | 2014 |
